AR128323A1 - Inhibidores de parp7 - Google Patents
Inhibidores de parp7Info
- Publication number
- AR128323A1 AR128323A1 ARP230100145A ARP230100145A AR128323A1 AR 128323 A1 AR128323 A1 AR 128323A1 AR P230100145 A ARP230100145 A AR P230100145A AR P230100145 A ARP230100145 A AR P230100145A AR 128323 A1 AR128323 A1 AR 128323A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- ring
- haloalkyl
- halogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101000735473 Homo sapiens Protein mono-ADP-ribosyltransferase TIPARP Proteins 0.000 title 1
- 102100034905 Protein mono-ADP-ribosyltransferase TIPARP Human genes 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000001188 haloalkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 150000002431 hydrogen Chemical class 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000002837 carbocyclic group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 150000001721 carbon Chemical group 0.000 abstract 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 5
- 125000003003 spiro group Chemical group 0.000 abstract 5
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de fórmula (1) como inhibidores de poli(ADP-ribosa) polimersa 7 (PARP7), métodos para prepararlos, composiciones farmacéuticas que los contienen y su uso en métodos de tratamiento, prevención y/o mejora de enfermedades o trastornos que involucran PARP7. Reivindicación 1: Un compuesto de fórmula (1) o un tautómero de este, profármaco de este, N-óxido de este, estereoisómero de este, éster farmacéuticamente aceptable de este o sal farmacéuticamente aceptable de este; en donde cada - - - - - - (línea punteada) representa independientemente un enlace opcional; W¹, W², W³ y W⁴ se seleccionan independientemente de N, NR¹, CR¹ y CR¹R¹ᵃ; cada aparición de R¹ y R¹ᵃ se selecciona independientemente de hidrógeno, hidroxilo, halógeno, nitro, haloalquilo sustituido o no sustituido, alquilo sustituido o no sustituido y amino sustituido o no sustituido; L¹ se selecciona de -(CRᵃRᵇ)ₙ-, -(CRᵃRᵇ)ₙ-O-, -C(Rᵃ)=C(Rᵇ)-, -O-, -NRᵃ, -(CRᵃRᵇ)ₙ-NRᵃ-, -S-, -S(O)- y -S(O)₂; L² está ausente o se selecciona de -(CRᵃRᵇ)ₙ-, -(CRᵃRᵇ)ₙ-O-, -C(Rᵃ)=C(Rᵇ)-, -O-, -NRᵃ, -(CRᵃRᵇ)ₙ-NRᵃ-, -S-, -S(O)- y -S(O)₂; cada aparición de Rᵃ y Rᵇ se selecciona independientemente de hidrógeno, halógeno, haloalquilo, hidroxi, amino sustituido o no sustituido, aminoalquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, haloalcoxi sustituido o no sustituido y alquilo sustituido o no sustituido; o tanto Rᵃ como Rᵇ junto con el átomo de carbono al que están unidos forman un grupo carbonilo, grupo espiro, anillo carbocíclico sustituido o no sustituido o anillo heterociclilo sustituido o no sustituido; R² y R³ se seleccionan independientemente de hidrógeno, halógeno, haloalquilo, hidroxi, amino sustituido o no sustituido, aminoalquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, haloalcoxi sustituido o no sustituido y alquilo sustituido o no sustituido; o tanto R² como R³ junto con el átomo de carbono al que están unidos forman un grupo carbonilo, grupo espiro, anillo carbocíclico sustituido o no sustituido o anillo heterociclilo sustituido o no sustituido; R²ᵃ y R³ᵃ se seleccionan independientemente de hidrógeno, halógeno, haloalquilo, hidroxi, amino sustituido o no sustituido, aminoalquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, haloalcoxi sustituido o no sustituido y alquilo sustituido o no sustituido; o tanto R²ᵃ como R³ᵃ pueden tomarse juntos con el átomo de carbono al que están unidos para formar un grupo carbonilo, grupo espiro, anillo carbocíclico sustituido o no sustituido o anillo heterociclilo sustituido o no sustituido; Z es CH o N; el anillo de fórmula (2) es de fórmula (i), (ii), (iii), o (iv); con las condiciones de que (a) cuando el anillo es (i), cada aparición de R⁴ y R⁴ᵃ se selecciona independientemente de hidrógeno, hidroxilo, halógeno, haloalquilo sustituido o no sustituido, alquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, hidroxialquilo sustituido o no sustituido y carbociclilo sustituido o no sustituido; o tanto R⁴ como R⁴ᵃ junto con el átomo de carbono al que están unidos pueden formar un grupo carbonilo, grupo espiro, anillo carbocíclico sustituido o no sustituido o anillo heterociclilo sustituido o no sustituido; (b) cuando el anillo es (ii), cada aparición de R⁴ y R⁴ᵃ se selecciona independientemente de hidrógeno, hidroxilo, halógeno, haloalquilo sustituido o no sustituido, alquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, hidroxialquilo sustituido o no sustituido y carbociclilo sustituido o no sustituido; (c) cuando el anillo es (iii), cada aparición de R⁴ y R⁴ᵃ se selecciona independientemente de hidrógeno, hidroxilo, halógeno, haloalquilo sustituido o no sustituido, alquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, hidroxialquilo sustituido o no sustituido y carbociclilo sustituido o no sustituido; o tanto R⁴ como R⁴ᵃ junto con el átomo de carbono al que están unidos pueden formar un grupo carbonilo, grupo espiro, anillo carbocíclico sustituido o no sustituido o anillo heterociclilo sustituido o no sustituido; y (d) cuando el anillo es (iv), cada aparición de R⁴ y R⁴ᵃ se selecciona independientemente de hidrógeno, hidroxilo, halógeno, haloalquilo sustituido o no sustituido, alquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, hidroxialquilo sustituido o no sustituido y anillo carbociclilo sustituido o no sustituido; X está ausente o se selecciona de -C(O)-, -NH-, -S-, -S(O)- y S(O)₂; Y se selecciona de alquilo sustituido o no sustituido, haloalquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heterociclilo sustituido o no sustituido y heteroarilo sustituido o no sustituido; m es 0, 1 o 2; y cada aparición de n es independientemente 1, 2 o 3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202241003918 | 2022-01-24 | ||
| IN202241025747 | 2022-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128323A1 true AR128323A1 (es) | 2024-04-17 |
Family
ID=85173012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100145A AR128323A1 (es) | 2022-01-24 | 2023-01-23 | Inhibidores de parp7 |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR128323A1 (es) |
| TW (1) | TW202340175A (es) |
| WO (1) | WO2023139536A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202519233A (zh) * | 2023-11-13 | 2025-05-16 | 大陸商康百達（四川）生物醫藥科技有限公司 | 一種parp7抑制劑聯合用藥的藥物組合及其治療腫瘤的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| WO2016116602A1 (en) * | 2015-01-23 | 2016-07-28 | Astrazeneca Ab | Treatment of cancer |
| CN110698411B (zh) * | 2018-07-09 | 2023-05-09 | 四川大学 | 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途 |
| CN115490671B (zh) * | 2022-10-21 | 2024-05-14 | 水木未来(北京)科技有限公司 | Parp7抑制剂及其制备方法 |
-
2023
- 2023-01-20 WO PCT/IB2023/050507 patent/WO2023139536A1/en not_active Ceased
- 2023-01-23 AR ARP230100145A patent/AR128323A1/es unknown
- 2023-01-30 TW TW112103120A patent/TW202340175A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023139536A1 (en) | 2023-07-27 |
| TW202340175A (zh) | 2023-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR086181A2 (es) | Metodo para preparar inhibidores macrociclicos inhibidores de serina proteasas del virus de la hepatitis c | |
| AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR045529A1 (es) | Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi | |
| ZA200603474B (en) | Alkoxy substituted imidazoquinolines | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| AR070513A1 (es) | Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR123848A1 (es) | Compuestos espiro heterocíclicos y métodos de uso | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR120773A1 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona como reductor de la actividad de la proteína wiz | |
| AR094646A1 (es) | Morfinanos sustituidos y su uso | |
| AR062680A1 (es) | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR109650A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| MX2010008363A (es) | Derivados de arilamida diazepinopirimidona sustituidos para el tratamiento de enfermedades neurodegenerativas causadas por la actividad anormal de gsk3-beta. | |
| AR087793A1 (es) | Compuestos de benzofurano sustituido y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| BR112020023115A2 (pt) | inibidores da via integrada de resposta a tensão |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |